Influences of inhaling glucocorticoid on sIgA and HBD-2,3 in pharyngeal mucosa of and T cell subsets in blood of patients with chronic persistent asthma

Abstract

Objective:The aim of this study was to investigate the inhaled glucocorticoid therapy affects sIgA and HBD 2,3 secreted by mucous membrane of throat and T lymphocyte subsets in patients with chronic persistent asthma. Method:One hundred patients diagnosed with chronic persistent asthma were randomly divided into control group (submitted to conventional non-hormonal therapy) and treatment group (submitted to inhaled glucocorticoid therapy) with 50 cases in each group. Ventolin aerosol had been promised in on demand use and the dosage of nonhormonal drugs should be adjusted according to the severity of illness in each group. No matter if asthma was fully under control or not, the observation would be terminated in 3 months. The secretion samples of pharyngeal mucosa and venous blood samples had been collected before and after treatment. The content of sIgA, HBD-2 and HBD-3 were detected by ELISA method. T lymphocyte subsets were detected by flow cytometry.Result:Compared with control group, the content of sIgA, HBD-2 and HBD-3 were lower in treatment group(P<0.05). Nevertheless, there were no significant differences of T lymphocyte subsets including CD3+,CD4+ and CD4+/CD8+ between two groups(P>0.05).Conclusion:The inhaled glucocorticoid therapy could bring adverse effects on the immune function of local mucous membrane in patients with asthma, with no significant effect on peripheral blood T cell subsets.